Recce Pharmaceuticals Management
Management criteria checks 3/4
Recce Pharmaceuticals' CEO is James Graham, appointed in Aug 2020, has a tenure of 3.92 years. total yearly compensation is A$774.73K, comprised of 71.1% salary and 28.9% bonuses, including company stock and options. directly owns 3.05% of the company’s shares, worth $2.06M. The average tenure of the management team and the board of directors is 3.9 years and 5.6 years respectively.
Key information
James Graham
Chief executive officer
AU$774.7k
Total compensation
| CEO salary percentage | 71.1% |
| CEO tenure | 3.9yrs |
| CEO ownership | 3.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$11m |
| Sep 30 2023 | n/a | n/a | -AU$12m |
| Jun 30 2023 | AU$775k | AU$551k | -AU$13m |
| Mar 31 2023 | n/a | n/a | -AU$14m |
| Dec 31 2022 | n/a | n/a | -AU$15m |
| Sep 30 2022 | n/a | n/a | -AU$13m |
| Jun 30 2022 | AU$548k | AU$328k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$10m |
| Dec 31 2021 | n/a | n/a | -AU$8m |
| Sep 30 2021 | n/a | n/a | -AU$11m |
| Jun 30 2021 | AU$2m | AU$294k | -AU$14m |
| Mar 31 2021 | n/a | n/a | -AU$13m |
| Dec 31 2020 | n/a | n/a | -AU$13m |
| Sep 30 2020 | n/a | n/a | -AU$9m |
| Jun 30 2020 | AU$216k | AU$187k | -AU$4m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$3m |
| Sep 30 2019 | n/a | n/a | -AU$3m |
| Jun 30 2019 | AU$177k | AU$155k | -AU$3m |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | n/a | n/a | -AU$2m |
| Sep 30 2018 | n/a | n/a | -AU$2m |
| Jun 30 2018 | AU$160k | AU$142k | -AU$2m |
Compensation vs Market: James's total compensation ($USD512.42K) is about average for companies of similar size in the US market ($USD685.12K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Graham
3.9yrs
Tenure
AU$774,727
Compensation
Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.3yrs | AU$369.85k | 0.14% A$ 93.3k | |
| CEO, MD & Executive Director | 3.9yrs | AU$774.73k | 3.05% A$ 2.1m | |
| Chief Scientific Director & Executive Director | 3.8yrs | AU$539.34k | 1.22% A$ 823.6k | |
| Principal Quality Chemist & Executive Director | no data | AU$306.76k | 0.14% A$ 91.7k | |
| Principal Engineer & Head of Manufacturing | no data | AU$319.12k | 0.030% A$ 20.4k | |
| Chief Medical Advisor & Independent Non Executive Director | no data | AU$72.50k | 0.057% A$ 38.6k | |
| Chief Financial Officer | 6.7yrs | no data | no data | |
| Head of Marketing | 4.5yrs | no data | no data | |
| Company Secretary | 1.8yrs | no data | no data |
3.9yrs
Average Tenure
Experienced Management: RECE.F's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.3yrs | AU$369.85k | 0.14% A$ 93.3k | |
| CEO, MD & Executive Director | 9.1yrs | AU$774.73k | 3.05% A$ 2.1m | |
| Chief Scientific Director & Executive Director | 9.1yrs | AU$539.34k | 1.22% A$ 823.6k | |
| Principal Quality Chemist & Executive Director | 5yrs | AU$306.76k | 0.14% A$ 91.7k | |
| Chief Medical Advisor & Independent Non Executive Director | 4yrs | AU$72.50k | 0.057% A$ 38.6k | |
| Non-Executive Director | 1.8yrs | AU$392.15k | 0.012% A$ 7.9k |
5.6yrs
Average Tenure
Experienced Board: RECE.F's board of directors are considered experienced (5.6 years average tenure).